logo
Growth Investors: Industry Analysts Just Upgraded Their Core Lithium Ltd (ASX:CXO) Revenue Forecasts By 13%

Growth Investors: Industry Analysts Just Upgraded Their Core Lithium Ltd (ASX:CXO) Revenue Forecasts By 13%

Yahoo7 days ago

Core Lithium Ltd (ASX:CXO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply increased their revenue numbers, with a view that Core Lithium will make substantially more sales than they'd previously expected.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
Following the upgrade, the consensus from four analysts covering Core Lithium is for revenues of AU$675k in 2025, implying a disturbing 99% decline in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of AU$595k in 2025. It looks like there's been a clear increase in optimism around Core Lithium, given the solid increase in revenue forecasts.
See our latest analysis for Core Lithium
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Core Lithium's past performance and to peers in the same industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 99% by the end of 2025. This indicates a significant reduction from annual growth of 75% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 6.5% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Core Lithium is expected to lag the wider industry.
The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They also expect company revenue to perform worse than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Core Lithium.
Analysts are definitely bullish on Core Lithium, but no company is perfect. Indeed, you should know that there are several potential concerns to be aware of, including a short cash runway. For more information, you can click through to our platform to learn more about this and the 2 other risks we've identified .
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AOFAR Officially Launches GX6: The Top Budget Rechargeable Golf Rangefinder for 2025
AOFAR Officially Launches GX6: The Top Budget Rechargeable Golf Rangefinder for 2025

Associated Press

time4 minutes ago

  • Associated Press

AOFAR Officially Launches GX6: The Top Budget Rechargeable Golf Rangefinder for 2025

NEW YORK, June 28, 2025 /CNW/ -- AOFAR today announced the release of the GX6 Golf Rangefinder, a leading choice for golfers seeking the best rechargeable golf rangefinder. The GX6 offers slope-adjusted distance, ultra-fast 0.02-second flag lock, a powerful magnetic cart mount, and modern USB-C rechargeable power, bringing high-end features to budget-conscious players. Weighing only 162g, the GX6 is one of the lightest golf rangefinders in its class, providing a comfortable and intuitive experience on the course. Its advanced optics deliver crisp visuals at 7× magnification with slope mode that can be toggled for tournament play. The built-in N52-grade magnetic mount allows golfers to securely attach the device to carts or clubs for fast, convenient access. The GX6's USB-C rechargeable battery delivers up to 12,000 distance measurements on a single charge, offering superior convenience and cost-efficiency compared to traditional battery-powered rangefinders. It's a 0.02-second flag lock with vibration feedback that ensures quick, accurate yardages, a must-have for faster-paced rounds. 'The GX6 delivers exceptional value for golfers looking to upgrade their gear in 2025,' said an AOFAR CEO, Mr Ding. 'It combines speed, lightweight design, rechargeable convenience, and tournament-ready accuracy — all for under $70. It's ideal for casual golfers, beginners, or anyone moving up from older battery-powered models.' Priced at just $69, the AOFAR GX6 Rechargeable Golf Rangefinder is now available on Amazon US and About AOFAR AOFAR is a global brand specializing in laser rangefinders and precision optics. From golfers to hunters and outdoor explorers, AOFAR delivers pro-grade performance at an accessible price. Learn more at Media Contact: Marketing director: Kris Ding Email: [email protected] View original content to download multimedia: SOURCE AOFAR

Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) to Contact the Firm Before Lead Plaintiff Deadline on August 25, 2025
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) to Contact the Firm Before Lead Plaintiff Deadline on August 25, 2025

Associated Press

time4 minutes ago

  • Associated Press

Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) to Contact the Firm Before Lead Plaintiff Deadline on August 25, 2025

NEW YORK, NY - June 28, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025 (the 'Class Period'). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 25, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. Hims & Hers operates a telehealth platform that connects customers to licensed healthcare professionals and offers a range of both prescription and non-prescription health and wellness products. On May 20, 2024, the Company announced the addition of GLP-1 injections to its comprehensive weight loss portfolio. Hims & Hers stated that '[p]roviding access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic(R) and Wegovy(R) without navigating the shortages and costs that are currently limiting access to the branded medications.' On April 29, 2025, Hims & Hers announced the first-step in a long-term collaboration with Novo Nordisk by providing 'a bundled offering of Novo Nordisk's FDA-approved Wegovy(R) on the Hims & Hers platform.' Then, on June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating the collaboration with Hims & Hers, including that 'direct access to Wegovy(R) will no longer be available' to Hims & Hers, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy(R) that put patient safety at risk.' The press release stated that Hims & Hers 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'' The press release further stated '[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China' that the 'FDA has never authorized or approved' according to a report from the Brookings Institute. Following this news, the price of Hims & Hers stock fell $22.24 per share, over 34%, to close at $41.98 per share on June 23, 2025. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. View the original release on

Americans Cash Out on Gold Coins as Asian Investors Bulk Up
Americans Cash Out on Gold Coins as Asian Investors Bulk Up

Bloomberg

time26 minutes ago

  • Bloomberg

Americans Cash Out on Gold Coins as Asian Investors Bulk Up

Americans who once snapped up gold bars and coins are offloading the assets while their Asian counterparts show no letup in bullion buying, a sign investors on opposite sides of the world have different outlooks on the global economy. The divergence suggests US residents who stash bars and coins at home or in safe deposit boxes — akin to stock market day traders — are more at ease about US President Donald Trump's tariffs, rising government debt and geopolitical tensions. And, they're ready to cash in after the metal's stunning rally over the past two years.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store